On the basis of therapy, the China hypophosphatasia therapeutics market can be segmented into enzyme replacement therapy and immunoglobulin therapy. Enzyme replacement therapy using bone-targeting recombinant alkaline phosphatase, or Asfotase alfa (Strensiq), is used as first-line therapy in infants, children, and some adults with HPP. The drug may be used in addition to supportive care to decrease the morbidity associated with the disease.
Supportive treatments for HPP are directed toward specific symptoms and complications. Treatment may require a team of specialists. Paediatricians, orthopaedic surgeons, pain management specialists and other healthcare professionals may be needed for comprehensive treatment.
By Distribution Channels:
On the basis of distribution channels, the China hypophosphatasia therapeutics market can be segmented into retail, online and hospital pharmacies. During the forecast period (2019-2028) the hospital pharmacies segment generates the highest revenue due to most of the major products being prescription products, which are available in hospital pharmacies. Retail and online pharmacies are second largest distribution channels during the forecast period (2019-2028).
By Drug Type:
On the basis of drug type, the China hypophosphatasia therapeutics market can be segmented into Asfotase alfa, non–steroidal anti-inflammatory drugs and thiazide diuretics. Non-steroidal anti-inflammatory drugs (NSAIDs) may help bone and joint pain. NSAIDs require caution and monitoring for side effects (e.g., they can hurt the stomach and kidneys), especially in excess and if used too long. Other supplementary medications such as Vitamin B6 and should avoid the bisphosphonates (These drugs may worsen HPP or cause symptoms in individuals with undiagnosed HPP). Vitamin B6 can help control specific seizures in severely affected infants.
Some of the key players in China’s hypophosphatasia therapeutics market are Alexion Pharmaceuticals Inc; Novartis AG.
STRENSIQ is an innovative enzyme replacement therapy approved for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP), by Alexion Pharmaceuticals.
Alexion has its presence in China but the drug is not approved in China. Strensiq has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Ministry of Health, Labour and Welfare (MHLW).
Therapies under study- A clinical study conducted by Novartis Pharmaceuticals in Germany: anti-sclerostin antibody BPS804 for the treatment of HPP.